This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allscripts' Latest Initiative Eradicates Price Ambiguity
by Zacks Equity Research
Lately, Allscripts' (MDRX) management has been focusing on various restructuring initiatives, research and development plans and launch of exclusive products.
DaVita's (DVA) Green Initiatives Win a Coveted Golden Reward
by Zacks Equity Research
DaVita's (DVA) environment-friendly operations are likely to enhance the company's long-term sustainable growth. Also, strong patient services drive DaVita's success story.
Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Baxter (BAX) reaches a 52-week high on the back of an impressive product line. Buoyed by last quarter's stellar growth in earnings and sales, the company also raises long-term outlook.
Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Inogen (INGN) develops, manufactures and markets POCs. The company's direct-to-customer business model lent it a leading position in the oxygen therapy space.
The Cooper Companies (COO) Beats Earnings Estimates in Q3
by Zacks Equity Research
The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.
NxStage System One Gets FDA Nod for Solo Home Hemodialysis
by Zacks Equity Research
The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash
by Zacks Equity Research
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash
Veeva Systems (VEEV) Beats Q2 Earnings, Revenue Estimates
by Zacks Equity Research
Veeva Systems (VEEV) witnessed stellar numbers in the second quarter owing to strong adoption of products like Veeva Network, Veeva Align, Veeva OpenData and Veeva CRM Approved Email.
5 Bargain Breakout Stocks Offering Stunning Returns
by Swarup Gupta
The key to this kind of stock selection is to identify players that are trading within a narrow band.
Stryker Recalls Sage Unit Products, Guidance Takes a Hit
by Zacks Equity Research
Added to the voluntary recall, Stryker (SYK) also placed a temporary hold on certain cloth-based products. Share price of Stryker declined massively following the news.
Patterson Companies (PDCO) Beats on Q1 Earnings, Keeps View
by Zacks Equity Research
Patterson Companies' (PDCO) Animal Health business continues to contribute to the bottom line. Stable fiscal 2018 guidance instills investor confidence.
Civitas Solutions (CIVI) to Acquire Habilitative Services
by Zacks Equity Research
Civitas Solutions' (CIVI) proposed acquisition of Habilitative Services will aid the company in capturing the lucrative Minnesota market.
Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.
PerkinElmer Strong on Product Lineup Amid Integration Risks
by Zacks Equity Research
PerkinElmer's (PKI) expanding product portfolio helps it gain global market share. However, the company's regular acquisitions pose integration risks.
Will Cogentix Medical (CGNT) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cogentix Medical Inc (CGNT)
Cogentix (CGNT) Looks Good: Stock Moves Up 5.2% in Session
by Zacks Equity Research
Cogentix Medical, Inc. (CGNT) moved big mover last session, as its shares rose over 5% on the day.
New Strong Sell Stocks for March 29th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Trump Could Still Be a Threat to Medical Device Stocks
by Zacks Equity Research
The Republican healthcare bill, American Health Care Act (ACHA), which was released earlier this month with the target to repeal the Affordable Care Act (ACA), hasn't found favor with the masses.
Owens & Minor (OMI) Reaffirms Tepid 2017 Financial Guidance
by Zacks Equity Research
Owens & Minor Inc. (OMI) outlined its new strategic plan and reaffirmed the financial guidance.
TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4
by Zacks Equity Research
TrovaGene Inc. (TROV) reported loss of 31 cents per share in the fourth quarter of 2016, 2 cents wider than the Zacks Consensus Estimate.
Cogentix (CGNT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Cogentix Medical, Inc. (CGNT) reported adjusted loss of 14 cents per share in the fourth quarter of 2016.
Luminex Projects Strong Q4 Revenues, Issues 2017 Guidance
by Zacks Equity Research
Luminex Corporation (LMNX) announced that it expects revenues in the fourth quarter of 2016 to be approximately $72 million and approximately $271 million for full-year 2016.
PerkinElmer (PKI) to Acquire India-Based Tulip Diagnostics
by Zacks Equity Research
PerkinElmer, Inc. (PKI) announced that it has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd.
Allscripts (MDRX) Q4 Bookings Likely to Hit Record Levels
by Zacks Equity Research
Allscripts Healthcare Solutions Inc. (MDRX) recently provided a bullish update on bookings alongside providing a number of financial updates on fourth quarter 2016.
Air Methods (AIRM): Winter Hits December Passenger Count
by Zacks Equity Research
Air Methods Corporation (AIRM), reported tepid preliminary patient transport and tourism passenger data for the month of Dec 2016.